Understanding how prostate cancer changes and resists treatment using blood tests and advanced genetic techniques
Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making
This study is looking at how prostate cancer changes and becomes tougher to treat over time, and it’s for patients who want to help researchers find better ways to detect and treat their cancer by providing blood samples for analysis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11106139 on NIH RePORTER |
What this research studies
This research investigates the changes in prostate cancer as it progresses, particularly focusing on how the cancer adapts and becomes resistant to treatments. By analyzing blood samples and using advanced single-cell epigenomic techniques, the study aims to identify specific changes in the cancer's genetic makeup that could help in early detection and treatment decisions. Patients may provide blood samples that will be analyzed to understand the cancer's behavior and response to therapies. The goal is to improve outcomes for patients with advanced prostate cancer by tailoring treatments based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced prostate cancer, particularly those experiencing treatment resistance.
Not a fit: Patients with early-stage prostate cancer or those not undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of aggressive prostate cancer and more effective personalized treatment strategies.
How similar studies have performed: Other research has shown promising results using similar epigenomic approaches to understand cancer progression and treatment resistance.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Freedman, Matthew L — Dana-Farber Cancer Inst
- Study coordinator: Freedman, Matthew L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.